Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma.
Georgina V LongAxel HauschildMario SantinamiJohn M KirkwoodVictoria AtkinsonMario MandalaBarbara MerelliVanna Chiarion SileniMarta NyakasAndrew HaydonCaroline DutriauxCaroline RobertLaurent MortierJacob SchachterDirk SchadendorfThierry LesimpleRuth PlummerJames LarkinMonique TanSachin Bajirao AdnaikPaul BurgessTarveen JandooReinhard DummerPublished in: The New England journal of medicine (2024)
V600E mutation, the results suggest that the risk of death was 25% lower with combination therapy. (Funded by GlaxoSmithKline and Novartis; COMBI-AD ClinicalTrials.gov number, NCT01682083; EudraCT number, 2012-001266-15.).